Medicinova, Inc. (MNOV)

PHARMACEUTICAL PREPARATIONS

Medicinova, Inc. (MNOV) is listed on Nasdaq, where it has traded since December 7, 2006.

Listed On
Nasdaq
Listed Since
December 7, 2006
Employees
6
Market Cap
$127M

About Medicinova, Inc.

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 27 institutions reported holding MNOV, with 5.2 million shares worth $6.8 million in aggregate. The largest reported holder was Essex Woodlands Management, with 1.1 million shares worth $1.5 million. Of the 5 largest holders listed below, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter.

InstitutionSharesValueQuarter change
Essex Woodlands Management1,105,941$1MUnchanged
Vanguard907,259$1MUnchanged
BlackRock752,091$993KAdded 6.54%
Citigroup635,715$839KUnchanged
Geode Capital Management539,312$712KReduced 0.83%

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is MNOV?

Medicinova, Inc. (MNOV) is listed on Nasdaq, where it has traded since December 7, 2006.

Who are the largest institutional holders of MNOV?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of MNOV were Essex Woodlands Management, Vanguard and BlackRock.

How many institutions own MNOV?

27 institutions reported a position in MNOV for the quarter ended June 30, 2026, worth $6.8 million in total.

Did institutions buy or sell MNOV last quarter?

Of the 5 largest reported holders, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for MNOV.

Every reported institutional holder, plus insider and congressional trades in MNOV, on SentiSense.